- Natural SHP2 Inhibitors
- Synthetic SHP2 Inhibitors
SHP2 Inhibitors Market size was valued at USD XXX million in 2022 and is expected to grow at a XX% CAGR from 2023 to 2029. SHP2 inhibitors block the pathway leading to KRAS G12C activation, which shifts the equilibrium towards inactive form, which has been shown preclinically to increase the target pool for KRAS inhibitors. The growing incidence of autoimmune disorder, metabolic disorders, and cancer across the globe is expected to drive the growth for SHP2 inhibitors market over the forecast period. in addition, increasing investments by pharmaceutical companies in research and development of developing novel SHP2 inhibitors along with the advancement of technologies leading to effective and safe SHP2 inhibitors is expected to propel the growth of SHP2 inhibitors market at a significant rate over the forecast period. furthermore, growing focus on precision medicine and targeted therapies for the treatment of various diseases such as cancer, autoimmune disease, metabolic disorder, and others are expected to aid the growth of SHP2 inhibitors market in the study period. However, factors like limited availability of targeted therapy option for treatment of SHP2 associated disease, high cost of development and clinical trials of SHP2 inhibitors, strict regulatory requirement for the approval of drug are expected to hinder the growth of SHP2 inhibitors market over the forecast period. In addition, the risk of drug resistance and side effects associated with the SHP2 inhibitors are anticipated to limit the growth of SHP2 inhibitors market over the forecast years. However, increasing healthcare expenditure, rising burden of disease, and development of personalized therapeutic option for treatment of cancer and other disease are expected to open up significant opportunities for market players in SHP2 inhibitors market over the forecast period. Geographically, North America region held the major market share in 2022 and is expected to dominate the global SHP2 inhibitors market in the forecasted years.
Recent SHP2 Inhibitors Market Key Developments:
In June 2020, AbbVie announced their strategic collaboration with Jacobio to advance the SHP2 Inhibitors.
SHP2 Inhibitors Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
X%
Largest Market
North America
Fastest Growing Market
Europe
SHP2 Inhibitors Market Dynamics
The SHP2 inhibitors market is expected to grow over the forecasted period due to the increasing incidence of cancer, autoimmune disorder, metabolic disease across the globe. Cancer is the one of the leading causes for death globally. For instance, according to the World Health Organization, around 9.6 million deaths were registered due to cancer in 2018. In addition, autoimmune disease and metabolic disorder also have a significant effect on the world population. These diseases require specific therapy or treatment to improve the quality of life of patients. The inhibition of SHP2 inhibitors leads to the suppression of cell growth, proliferation, and cancer progression. The development of SHP2 inhibitors helps in the targeted treatment option of cancer patients across the globe.
North America Got Highest Share
SHP2 Inhibitors Market Regional Analysis
The SHP2 inhibitors market is segmented based on regions into North America, Asia-pacific, Europe, Latin America, and the Middle East and Africa. The North America SHP2 inhibitors market is likely to hold a significant revenue share, and in the forecasted years, it is predicted to increase rapidly due to the presence of numerous pharmaceutical and biotech companies engaged in research and development activities to develop effective and efficient SHP2 inhibitors in this region. Europe region is expected to have a fastest significant growth over the forecast period owing to increasing focus on precision medicines and targeted therapies in developed countries such as Germany, and UK.
Latin America
Europe
Asia Pacific
Middle East
North America
SHP2 Inhibitors Market Segmentation
By Type
By Application
- Autoimmune Disorder
- Inflammatory Disease
- Others
By Distribution channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
SHP2 Inhibitors Market was valued at USD XXX million in 2022 and is expected to grow at a XX% CAGR from 2023 to 2029.
The SHP2 Inhibitors market is segmented based on type, application, distribution channel, end user, and geography
The leading players in the global SHP2 Inhibitors market are Genentech Inc, Eli Lilly & Company, Merck & Co, AbbVie Inc, Pfizer Inc, Astellas Pharma Inc, Vertex Pharmaceutical Incorporated, AstraZeneca Plc, Novartis AG, Sanofi S.A, Amgen Inc.
High cost of treatment, along with high risk of developing resistance to drug is expected to hinder the growth of SHP2 market over the forecast period.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
- Genentech Inc
- Eli Lilly & Company
- Merck & Co
- AbbVie Inc
- Pfizer Inc
- Astellas Pharma Inc
- Vertex Pharmaceutical Incorporated
- AstraZeneca Plc
- Novartis AG
- Sanofi S.A
- Amgen Inc.